![]() In the phase 3 KEYNOTE-048 (NCT02358031), 882 patients with metastatic HNSCC were randomly assigned to pembrolizumab, pembrolizumab plus platinum-based chemotherapy and 5-fluorouracil (5-FU), or the EXTREME regimen consisting of cetuximab (Erbitux) plus platinum-based chemotherapy and 5-FU. “Overall, these data support the use of pembrolizumab and pembrolizumab plus chemotherapy as first-line treatment of patients with relapsed and/or metastatic HNSCC,” he said. ![]() Similarly, the median PFS2 was superior in the pembrolizumab/chemotherapy arm (n = 278) 10.3 vs 9.0 months HR, 0.74 95% CI, 0.62-0.88). The median PFS2 was 9.0 months for both groups (HR, 0.90 95% CI, 0.75-1.07).įor those in the total population assigned to pembrolizumab/chemotherapy (n = 281), the 24-month PFS2 rate was 21.4% versus 10.5% in favor of the experimental arm. Harrington, MBBS, PhD, added that the combination of pembrolizumab plus chemotherapy also extended PFS2 for the total study population.Īmong the total population, the 24-month PFS2 rate was 19.7% among those assigned to pembrolizumab (n = 301) compared with 11.4% in the EXTREME arm (n = 300). In findings presented at the 2020 ASCO Virtual Scientific Meeting, lead author Kevin J. Pembrolizumab induced better PFS2 outcomes both alone and in combination with chemotherapy. Treatment with pembrolizumab (Keytruda) improved progression-free survival after subsequent therapy (PFS2) for patients with PD-L1-positive, relapsed/refractory head and neck squamous cell carcinoma (HNSCC) compared with the EXTREME regimen, according to an analysis of the KEYNOTE-048 trial.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |